Pub Date : 2023-12-01DOI: 10.29158/JAAPL.230092-23
Kristen C Ochoa
{"title":"Letters.","authors":"Kristen C Ochoa","doi":"10.29158/JAAPL.230092-23","DOIUrl":"10.29158/JAAPL.230092-23","url":null,"abstract":"","PeriodicalId":47554,"journal":{"name":"Journal of the American Academy of Psychiatry and the Law","volume":"51 4","pages":"608"},"PeriodicalIF":2.1,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138809503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-01DOI: 10.29158/JAAPL.230064-23
Susan Hatters Friedman, Renée M Sorrentino, Daniel Riordan, Kerri Eagle
{"title":"Evaluating Female Sex Offenders Without Prejudice.","authors":"Susan Hatters Friedman, Renée M Sorrentino, Daniel Riordan, Kerri Eagle","doi":"10.29158/JAAPL.230064-23","DOIUrl":"10.29158/JAAPL.230064-23","url":null,"abstract":"","PeriodicalId":47554,"journal":{"name":"Journal of the American Academy of Psychiatry and the Law","volume":"51 4","pages":"466-474"},"PeriodicalIF":2.1,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138809555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-01DOI: 10.29158/JAAPL.230080-23
Declan J Grabb, Cara Angelotta
{"title":"Emerging Forensic Implications of the Artificial Intelligence Revolution.","authors":"Declan J Grabb, Cara Angelotta","doi":"10.29158/JAAPL.230080-23","DOIUrl":"10.29158/JAAPL.230080-23","url":null,"abstract":"","PeriodicalId":47554,"journal":{"name":"Journal of the American Academy of Psychiatry and the Law","volume":"51 4","pages":"475-479"},"PeriodicalIF":2.1,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138809548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-01DOI: 10.29158/JAAPL.230091-23
Fred S Berlin
{"title":"In Reply.","authors":"Fred S Berlin","doi":"10.29158/JAAPL.230091-23","DOIUrl":"10.29158/JAAPL.230091-23","url":null,"abstract":"","PeriodicalId":47554,"journal":{"name":"Journal of the American Academy of Psychiatry and the Law","volume":"51 4","pages":"609-610"},"PeriodicalIF":2.1,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138809496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-01DOI: 10.29158/JAAPL.230104-23
Kristopher Kaliebe
{"title":"Letters.","authors":"Kristopher Kaliebe","doi":"10.29158/JAAPL.230104-23","DOIUrl":"10.29158/JAAPL.230104-23","url":null,"abstract":"","PeriodicalId":47554,"journal":{"name":"Journal of the American Academy of Psychiatry and the Law","volume":"51 4","pages":"608-609"},"PeriodicalIF":2.1,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138809579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-01DOI: 10.29158/JAAPL.230062-23
James B Reynolds
The procedures and outcomes of conditional release of insanity acquittees is a relatively neglected area of forensic psychiatric research. The release procedures vary in individual states, resulting in a wide range of approaches, from the careful selection of appropriate patients and strict monitoring in the community, to literally no mechanism for ensuring the future safety of such individuals. In North Carolina there are institutional barriers which even hinder research on the outcomes of such cases. Haroon and colleagues report on the post-release outcomes of insanity acquittees in North Carolina from 1996 to 2020. The findings of the researchers are analyzed in light of the lack of a formal post-release monitoring system in their state, contrasted with outcomes in states where a strict monitoring program is in place. Commentary is provided on the study findings, including associations between demographic, psychiatric, and criminological characteristics of insanity acquittees and release outcomes, as well as an apparent systemic bias against minority acquittees in the insanity commitment and release process in North Carolina. Further research on this important topic, from additional state jurisdictions, is recommended.
{"title":"The Value of Conditional Release for Insanity Acquittees.","authors":"James B Reynolds","doi":"10.29158/JAAPL.230062-23","DOIUrl":"https://doi.org/10.29158/JAAPL.230062-23","url":null,"abstract":"<p><p>The procedures and outcomes of conditional release of insanity acquittees is a relatively neglected area of forensic psychiatric research. The release procedures vary in individual states, resulting in a wide range of approaches, from the careful selection of appropriate patients and strict monitoring in the community, to literally no mechanism for ensuring the future safety of such individuals. In North Carolina there are institutional barriers which even hinder research on the outcomes of such cases. Haroon and colleagues report on the post-release outcomes of insanity acquittees in North Carolina from 1996 to 2020. The findings of the researchers are analyzed in light of the lack of a formal post-release monitoring system in their state, contrasted with outcomes in states where a strict monitoring program is in place. Commentary is provided on the study findings, including associations between demographic, psychiatric, and criminological characteristics of insanity acquittees and release outcomes, as well as an apparent systemic bias against minority acquittees in the insanity commitment and release process in North Carolina. Further research on this important topic, from additional state jurisdictions, is recommended.</p>","PeriodicalId":47554,"journal":{"name":"Journal of the American Academy of Psychiatry and the Law","volume":"51 3","pages":"353-356"},"PeriodicalIF":2.7,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10195402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-01DOI: 10.29158/JAAPL.230040-23
Lisa Harding
Ketamine is a dissociative anesthetic that has gained attention in the field of psychiatry because of its unique mechanism of action and potential for treating treatment-resistant psychiatric disorders. It has been used off label for decades to treat depression, anxiety, and chronic pain. One of the most significant advancements has been the U.S. Food and Drug Administration’s (FDA) approval of esketamine, the S enantiomer of racemic ketamine, for treatmentresistant depression (TRD) and depression with acute suicidal ideation. Unlike traditional antidepressants, which can take several weeks to start working, esketamine and ketamine can begin to alleviate symptoms within hours of administration. Esketamine is also the only antidepressant of its kind to be studied and approved by the FDA for depressive symptoms in a suicidal population. Over the last five years there has been increased tension among medical providers regarding who is best suited to deliver care with ketamine and esketamine. Although the use of ketamine for depression and other psychiatric conditions has gained increasing attention, there is limited research available to support its use in many of the disorders for which it is used off label. Despite this lack of evidence, ketamine clinics have emerged as a popular alternative for patients who have not responded to traditional treatment options. In addition, the classification of the drug as a Schedule III (CIII) controlled substance and its potential for abuse and dependence raise significant concerns about its safety and appropriate use in medical settings. There is a pressing need for increased research and regulatory oversight into the potential risks and benefits of ketamine as a treatment for multiple psychiatric conditions. As the off-label use of ketamine for psychiatric disorders evolves as a therapeutic option, it is imperative that regulatory authorities promptly establish guidelines and regulations to promote its safe and effective use. This editorial examines the current state of knowledge regarding the use of ketamine and esketamine for psychiatric disorders and presents a framework for thinking through the challenges and opportunities for regulating the use of ketamine in psychiatry.
{"title":"Regulating Ketamine Use in Psychiatry.","authors":"Lisa Harding","doi":"10.29158/JAAPL.230040-23","DOIUrl":"https://doi.org/10.29158/JAAPL.230040-23","url":null,"abstract":"Ketamine is a dissociative anesthetic that has gained attention in the field of psychiatry because of its unique mechanism of action and potential for treating treatment-resistant psychiatric disorders. It has been used off label for decades to treat depression, anxiety, and chronic pain. One of the most significant advancements has been the U.S. Food and Drug Administration’s (FDA) approval of esketamine, the S enantiomer of racemic ketamine, for treatmentresistant depression (TRD) and depression with acute suicidal ideation. Unlike traditional antidepressants, which can take several weeks to start working, esketamine and ketamine can begin to alleviate symptoms within hours of administration. Esketamine is also the only antidepressant of its kind to be studied and approved by the FDA for depressive symptoms in a suicidal population. Over the last five years there has been increased tension among medical providers regarding who is best suited to deliver care with ketamine and esketamine. Although the use of ketamine for depression and other psychiatric conditions has gained increasing attention, there is limited research available to support its use in many of the disorders for which it is used off label. Despite this lack of evidence, ketamine clinics have emerged as a popular alternative for patients who have not responded to traditional treatment options. In addition, the classification of the drug as a Schedule III (CIII) controlled substance and its potential for abuse and dependence raise significant concerns about its safety and appropriate use in medical settings. There is a pressing need for increased research and regulatory oversight into the potential risks and benefits of ketamine as a treatment for multiple psychiatric conditions. As the off-label use of ketamine for psychiatric disorders evolves as a therapeutic option, it is imperative that regulatory authorities promptly establish guidelines and regulations to promote its safe and effective use. This editorial examines the current state of knowledge regarding the use of ketamine and esketamine for psychiatric disorders and presents a framework for thinking through the challenges and opportunities for regulating the use of ketamine in psychiatry.","PeriodicalId":47554,"journal":{"name":"Journal of the American Academy of Psychiatry and the Law","volume":"51 3","pages":"320-325"},"PeriodicalIF":2.7,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10137794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-01DOI: 10.29158/JAAPL.230070-23
Krista Ulisse, Aliana M. Abascal
{"title":"Defining the Term Mental Disorder in Nebraska’s Statute","authors":"Krista Ulisse, Aliana M. Abascal","doi":"10.29158/JAAPL.230070-23","DOIUrl":"https://doi.org/10.29158/JAAPL.230070-23","url":null,"abstract":"","PeriodicalId":47554,"journal":{"name":"Journal of the American Academy of Psychiatry and the Law","volume":"51 1","pages":"457 - 458"},"PeriodicalIF":2.7,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48943139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-01Epub Date: 2023-06-30DOI: 10.29158/JAAPL.230024-23
Haseeb Haroon, Nicole Wolfe, Sara Feizi, Peter Barboriak
Over the past two decades, an increasing proportion of North Carolina state psychiatric hospital beds have been used to house forensic patients. Insanity acquittees occupy almost all forensic-designated beds in the state. Despite the effect insanity acquittees have on state hospital use in North Carolina, outcomes for acquittees after they are released from the state hospital are unknown because of a lack of previous research. This study evaluates postrelease outcomes for insanity acquittees discharged from the North Carolina Forensic Treatment Program between 1996 and 2020. The study also describes the association between the demographic, psychiatric, and criminological characteristics of insanity acquittees and outcomes of recidivism or rehospitalization. The results show that insanity acquittees in North Carolina have higher rates of criminal recidivism than acquittees in other states. There is also evidence of systemic bias against minority race acquittees in the insanity commitment and release process in North Carolina. Outcomes for insanity acquittees released from the state Forensic Treatment Program could be improved through the introduction of evidence-based practices widely used in other states.
{"title":"Assessing Two Decades of Insanity Acquittee Release from the North Carolina Forensic Program.","authors":"Haseeb Haroon, Nicole Wolfe, Sara Feizi, Peter Barboriak","doi":"10.29158/JAAPL.230024-23","DOIUrl":"10.29158/JAAPL.230024-23","url":null,"abstract":"<p><p>Over the past two decades, an increasing proportion of North Carolina state psychiatric hospital beds have been used to house forensic patients. Insanity acquittees occupy almost all forensic-designated beds in the state. Despite the effect insanity acquittees have on state hospital use in North Carolina, outcomes for acquittees after they are released from the state hospital are unknown because of a lack of previous research. This study evaluates postrelease outcomes for insanity acquittees discharged from the North Carolina Forensic Treatment Program between 1996 and 2020. The study also describes the association between the demographic, psychiatric, and criminological characteristics of insanity acquittees and outcomes of recidivism or rehospitalization. The results show that insanity acquittees in North Carolina have higher rates of criminal recidivism than acquittees in other states. There is also evidence of systemic bias against minority race acquittees in the insanity commitment and release process in North Carolina. Outcomes for insanity acquittees released from the state Forensic Treatment Program could be improved through the introduction of evidence-based practices widely used in other states.</p>","PeriodicalId":47554,"journal":{"name":"Journal of the American Academy of Psychiatry and the Law","volume":"51 3","pages":"342-352"},"PeriodicalIF":2.7,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10191906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-01DOI: 10.29158/JAAPL.230063-23
Erik Roskes
{"title":"","authors":"Erik Roskes","doi":"10.29158/JAAPL.230063-23","DOIUrl":"https://doi.org/10.29158/JAAPL.230063-23","url":null,"abstract":"","PeriodicalId":47554,"journal":{"name":"Journal of the American Academy of Psychiatry and the Law","volume":"51 3","pages":"464"},"PeriodicalIF":2.7,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10211100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号